Pham Van Luan, MD., PhD
College of Health Sciences
Clinical Lecturer
108 Military Central Hospital
Associated Program Director
Biography
In 2013, Dr. Pham Van Luan earned his medical degree from the Military Medical Academy. He successfully defended his Ph.D. thesis in respiratory medicine at the 108 Institute of Clinical Medical and Pharmaceutical Sciences in 2023. He is currently a clinician at the 108 Military Central Hospital in Respiratory Medicine Department. Dr. Pham Van Luan has made important contributions to the fields of science and technology, including a number of ground-breaking studies that have gained recognition both domestically and abroad for their high scientific and practical worth.
In medical education, he currently serves as the Associate Program Director of the Internal Medicine Residency Program at the 108 Central Military Hospital. He is also an active member of various national and international scientific associations, including the Vietnam Respiratory Society, Vietnam Lung Association, and the Asia-Pacific Society of Respirology.
Moreover, he has presented at numerous national and international respiratory and oncology conferences, such as the Vietnam Respiratory Conference, Vietnam Oncology Conference, Asia-Pacific Society of Respirology (APSR) Congress, and the World Lung Cancer Conference. He is also the co-author of a reference book published in 2024, “Non-Small Cell Lung Cancer – An Approach from Diagnosis to Treatment.”
1. Preliminary results of stereotactic body radiotherapy using CyberKnife for early-stage non-small cell lung cancer – Journal of 108 Clinical Medicine and Pharmacy, Vol. 11, Special Issue 3/2016.
2. EGFR mutation rate and its correlation with clinical and subclinical characteristics in 320 non-small cell lung cancer patients treated at 108 Central Military Hospital – Journal of 108 Clinical Medicine and Pharmacy, Vol. 99-2017: 57-64.
3. Characteristics of aerobic bacteria identified by quantitative culture in patients with acute exacerbation of chronic obstructive pulmonary disease – Journal of 108 Clinical Medicine and Pharmacy, Vol. 12, Special Issue 11/2017: 241-247.
4. Epidermal growth factor receptor mutations in non-small cell lung cancer patients from a single institution in Vietnam – Journal of 108 Clinical Medicine and Pharmacy, Vol. 13, 9/2018: 7–12.
5. Characteristics of lung parenchymal and pulmonary artery lesions on 320-slice CT in patients with acute exacerbation of chronic obstructive pulmonary disease – Journal of 108 Clinical Medicine and Pharmacy, Vol. 11, Special Issue 9/2018.
6. Clinical characteristics of brain MRI in non-small cell lung cancer patients with brain metastases – Journal of Military Medical and Pharmaceutical, 2019, 44(1): 60-65.
7. Small cell lung cancer transformation in EGFR-TKI resistant lung adenocarcinoma patients: An unresolved issue – Journal of Clinical Medicine, No. 109, 7/2019: 14-17.
8. EGFR mutations and targeted therapy in stage IIIB and IV non-small cell lung cancer patients with positive EGFR mutations using Gefitinib – Journal of 108 Clinical Medicine and Pharmacy, Vol. 15, Special Issue 11/2019.
9. Real-world analysis of the effect of Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations – Therapeutic Advances in Medical Oncology, 2021;13: 1–7.
10. Comparison of pleural involvement in metastatic lung cancer and tuberculosis – Journal of 108 Clinical Medicine and Pharmacy, 2021; 4(16): 344–349.
September 2006 – August 2013: Medical Student – Military Medical Academy
August 2013 – Present: Clinician – Department of Respiratory Medicine, 108 Central Military Hospital
September 2023: PhD – 108 Military Central Hospital
